Groupe la Francaise raised its holdings in shares of STERIS plc (NYSE:STE - Free Report) by 15.4% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 13,834 shares of the medical equipment provider's stock after acquiring an additional 1,850 shares during the period. Groupe la Francaise's holdings in STERIS were worth $3,102,000 at the end of the most recent reporting period.
A number of other institutional investors and hedge funds have also bought and sold shares of STE. Select Equity Group L.P. grew its position in STERIS by 165.3% during the fourth quarter. Select Equity Group L.P. now owns 2,599,730 shares of the medical equipment provider's stock valued at $534,400,000 after acquiring an additional 1,619,796 shares during the last quarter. Massachusetts Financial Services Co. MA grew its stake in shares of STERIS by 9.1% during the first quarter. Massachusetts Financial Services Co. MA now owns 5,439,349 shares of the medical equipment provider's stock valued at $1,232,828,000 after buying an additional 452,146 shares during the last quarter. GAMMA Investing LLC grew its stake in shares of STERIS by 35,759.9% during the first quarter. GAMMA Investing LLC now owns 410,237 shares of the medical equipment provider's stock valued at $92,980,000 after buying an additional 409,093 shares during the last quarter. Nuveen LLC bought a new position in shares of STERIS during the first quarter valued at about $65,435,000. Finally, Wellington Management Group LLP grew its stake in shares of STERIS by 4,534.6% during the fourth quarter. Wellington Management Group LLP now owns 219,032 shares of the medical equipment provider's stock valued at $45,024,000 after buying an additional 214,306 shares during the last quarter. 94.69% of the stock is currently owned by institutional investors.
STERIS Stock Up 1.7%
NYSE STE opened at $251.7320 on Friday. The company has a debt-to-equity ratio of 0.27, a current ratio of 2.22 and a quick ratio of 1.53. The stock has a market capitalization of $24.79 billion, a PE ratio of 38.55 and a beta of 0.92. STERIS plc has a 1 year low of $200.98 and a 1 year high of $252.79. The business's 50-day moving average is $234.96 and its 200 day moving average is $230.58.
STERIS (NYSE:STE - Get Free Report) last posted its earnings results on Wednesday, August 6th. The medical equipment provider reported $2.34 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.32 by $0.02. The company had revenue of $1.40 billion for the quarter, compared to analysts' expectations of $1.36 billion. STERIS had a return on equity of 14.17% and a net margin of 11.61%.STERIS's quarterly revenue was up 8.8% on a year-over-year basis. During the same period last year, the firm earned $2.03 earnings per share. Sell-side analysts forecast that STERIS plc will post 9.08 earnings per share for the current year.
STERIS Increases Dividend
The firm also recently announced a quarterly dividend, which will be paid on Friday, September 26th. Investors of record on Thursday, September 4th will be paid a $0.63 dividend. The ex-dividend date of this dividend is Thursday, September 4th. This is a boost from STERIS's previous quarterly dividend of $0.57. This represents a $2.52 annualized dividend and a dividend yield of 1.0%. STERIS's payout ratio is 34.92%.
Wall Street Analyst Weigh In
STE has been the topic of a number of recent research reports. Stephens reaffirmed an "overweight" rating and set a $250.00 price objective on shares of STERIS in a research note on Thursday, May 15th. Morgan Stanley raised their price objective on STERIS from $276.00 to $295.00 and gave the company an "overweight" rating in a research note on Friday, August 8th. KeyCorp raised their price objective on STERIS from $277.00 to $288.00 and gave the company an "overweight" rating in a research note on Tuesday, July 22nd. Wall Street Zen raised STERIS from a "buy" rating to a "strong-buy" rating in a research note on Saturday, August 9th. Finally, JMP Securities raised their price objective on STERIS from $265.00 to $280.00 and gave the company a "market outperform" rating in a research note on Friday, May 16th. Six equities research analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the stock. According to MarketBeat.com, the company currently has an average rating of "Moderate Buy" and an average price target of $273.50.
Read Our Latest Analysis on STE
Insider Buying and Selling
In other STERIS news, CAO Karen L. Burton sold 7,900 shares of the firm's stock in a transaction dated Monday, August 11th. The shares were sold at an average price of $241.73, for a total value of $1,909,667.00. Following the completion of the sale, the chief accounting officer directly owned 5,994 shares in the company, valued at $1,448,929.62. This trade represents a 56.86% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at this link. Also, VP Renato Tamaro sold 3,204 shares of STERIS stock in a transaction that occurred on Wednesday, August 20th. The shares were sold at an average price of $249.24, for a total value of $798,564.96. Following the sale, the vice president directly owned 7,221 shares in the company, valued at approximately $1,799,762.04. The trade was a 30.73% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 36,335 shares of company stock valued at $8,822,302 over the last ninety days. Corporate insiders own 1.07% of the company's stock.
About STERIS
(
Free Report)
STERIS plc provides infection prevention products and services worldwide. It operates through four segments: Healthcare, Applied Sterilization Technologies, Life Sciences, and Dental. The Healthcare segment offers cleaning chemistries and sterility assurance products; automated endoscope reprocessing system and tracking products; endoscopy accessories, washers, sterilizers, and other pieces of capital equipment for the operation of a sterile processing department; and equipment used directly in the operating room, including surgical tables, lights, and connectivity solutions, as well as equipment management services.
See Also
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider STERIS, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and STERIS wasn't on the list.
While STERIS currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Fall 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
MarketBeat All Access